Get started
Author

Bernd Schlereth

Observed names: B. Schlereth, Schlereth Bernd, Schlereth, Bernd Johannes 1978-
Observed institutions: Merck KGaA, Darmstadt (Germany), University of Würzburg, Johnson & Johnson (Switzerland), Bavarian Nordic (Germany), Molecular Partners (Switzerland), Araris Biotech AG (Switzerland)
ORCID: 0009-0007-3408-5320
Observed ORCIDs: 0009-0007-3408-5320, 0009-0000-5146-708X
OpenAlex ID: A5025036739
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
2005 · Klaus Brischwein, Bernd Schlereth, et al. · Molecular Immunology · 260
BiTEs: bispecific antibody constructs with unique anti-tumor activity
2005 · Evelyn Wolf, Robert Hofmeister, et al. · Drug Discovery Today · 259
T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct
2003 · Torsten Dreier, Patrick A Baeuerle, et al. · The Journal of Immunology · 193
PDF
Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class
2007 · Klaus Brischwein, Larissa Parr, et al. · Journal of Immunotherapy · 188
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
2009 · Cornelia Haas, Eva Krinner, et al. · Immunobiology · 182
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine
2005 · Jens Vollmar, Nathaly Arndtz, et al. · Vaccine · 175
Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct
2005 · Bernd Schlereth, Iduna Fichtner, et al. · Cancer Research · 134
Successful Vaccine-Induced Seroconversion by Single-Dose Immunization in the Presence of Measles Virus-Specific Maternal Antibodies
2000 · Bernd Schlereth, John K. Rose, et al. · Journal of Virology · 104
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
2005 · Bernd Schlereth, Cornelia Quadt, et al. · Cancer Immunology Immunotherapy · 103
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases
2015 · Michela Silacci, Wibke Lembke, et al. · mAbs · 95
Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
2008 · Maria Amann, Klaus Brischwein, et al. · Cancer Research · 88
Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2007 · Scott A. Hammond, Ralf Lutterbuese, et al. · Cancer Research · 82
PDF
Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
2009 · Ralf Lutterbuese, Tobias Raum, et al. · Journal of Immunotherapy · 78
Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release
2009 · Maria Amann, Sandrine dÁrgouges, et al. · Journal of Immunotherapy · 64
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
2005 · Bernd Schlereth, Petra Kleindienst, et al. · Cancer Immunology Immunotherapy · 55
Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose
2003 · Bernd Schlereth, Linda Buonocore, et al. · Journal of General Virology · 50
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
2008 · Maria Amann, Matthias Friedrich, et al. · Cancer Immunology Immunotherapy · 40
Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model
2001 · Gerald Weidinger, Marion Ohlmann, et al. · Vaccine · 36
DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection
2000 · Bernd Schlereth, Paul-Georg Germann, et al. · Microbiology · 32
Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110
2008 · Juliane Witthauer, Bernd Schlereth, et al. · Breast Cancer Research and Treatment · 23
The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024 · Matteo Bianchi, Christian Reichen, et al. · Cancer Immunology Research · 17
PDF
Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model
2006 · Petra Lutterbuese, Klaus Brischwein, et al. · Cancer Immunology Immunotherapy · 15
Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC
2025 · Philipp Probst, Isabella Attinger-Toller, et al. · Molecular Cancer Therapeutics · 9
PDF
Abstract 7334: Targeting Nectin-4 with a first-in-class triple MMAE/dual TOP1i payload ADC showing synergistic and durable activity across all target expression levels and favorable tolerability
2025 · Isabella Attinger-Toller, Philipp Probst, et al. · Cancer Research · 6
Abstract 1890: A solution to T-cell engager toxicity: An anti-CD3 Prodrug DARPin (CD3-PDD) shows no toxicity, but potent anti-tumor activity in a humanized mouse model
2021 · Andreas Bosshart, Julia Katharina Ahlskog, et al. · Cancer Research · 3
Works count: 97
Citation count: 2,310
H-index: 20
I10-index: 22
Year
Topic
Type